• About
    • Company Overview
    • Management Team
    • Board of Directors
    • Science Advisors
    • Neurology Advisors
    • Ophthalmology Advisors
    • Contacts
  • Science
    • Publications
    • Collaborators
  • Pipeline
    • Infantile Neuroaxonal Dystrophy (INAD)
    • Friedreich’s Ataxia (FA)
    • Amyotrophic Lateral Sclerosis (ALS)
    • Progressive Supranuclear Palsy (PSP)
    • Dry AMD
    • Future Targets
  • Patient Resources
    • Expanded Access Policy
    • Clinical Trials
    • Additional Resources
  • News & Events
    • Press Releases
    • News
    • Events
    • Videos
  • Careers
HomeSciencePublicationsCase Report: Expanded Access Treatment of an Infantile Neuroaxonal Dystrophy (INAD) Patient with a Novel, Stabilized Polyunsaturated Fatty Acid Drug

Case Report: Expanded Access Treatment of an Infantile Neuroaxonal Dystrophy (INAD) Patient with a Novel, Stabilized Polyunsaturated Fatty Acid Drug

INAD is an ultra-rare inherited neurological disorder. It begins within the first few years of life, and leads to a progressive impairment of movement, cognition, and vision. Its prevalence is extremely rare (<1:200,000), and it is inherited in an autosomal recessive pattern. Disease onset may start at 6 months of age with slowing of motor and cognitive development and regression of previously acquired skills. This is accompanied by roving eye movements, strabismus and nystagmus. Hypotonia is initially accompanied by preserved / brisk reflexes and is more obvious in the lower than the upper extremities. Death usually occurs between the ages of 5 to 10 years, often from loss of bulbar function leading to aspirational pneumonia. The genetic basis of INAD are mutations in the PLA2G6 gene (chromosome 22q12-q13) which encodes an 85 kDa group IV calcium independent phospholipase A2β (iPLA2β). The enzyme is responsible for the selective hydrolysis of the sn-2 ester bond of glycerophospholipids to release free polyunsaturated fatty acids (PUFAs). This is a critical housekeeping function in all cells membranes but in particular those exposed to high oxidative stress such as mitochondrial membranes in high energy tissues.

Read more…

About
Science
  • Publications
Pipeline
  • Clinical
  • Preclinical
  • Future Targets
Patient Resources
  • Expanded Access Policy
News & Events
Careers
RETROTOPE, 4300 EL CAMINO REAL, SUITE 201, LOS ALTOS, CA 94022
Copyright ©️ 2015-2021 Retrotope Inc.
You are leaving Retrotope’s website. Retrotope does not guarantee the accuracy or completeness of the information contained on any third-party sites, nor does it endorse any of the opinions or information contained on those sites. Please click CONFIRM to continue. CONFIRM